Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Myelodysplastic Syndromes 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1Advanced Lung Neuroendocrine Tumor 1

Interventions

Cytarabine 18fludarabine phosphate 17Cyclophosphamide 12Busulfan 11Filgrastim 10Peripheral Blood Stem Cell Transplantation 9Etoposide 9Azacitidine 9Methotrexate 8Decitabine 8Antilymphocyte Serum 8Specimen Handling 7Daunorubicin 7Biopsy 7fludarabine 6Tacrolimus 6Stem Cell Transplantation 6Cyclosporine 6decitabine and cedazuridine drug combination 5Melphalan 5Idarubicin 5Topotecan 4Rituximab 4Radiotherapy 4Prednisone 4Mitoxantrone 4Methylprednisolone 4Injections 4venetoclax 3sargramostim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Myelodysplastic Syndromes × Photons × Clear all
NCT06888323 2026-04-13

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡